Sesame, the health-care marketplace, has unveiled an innovative clinical weight loss program that provides eligible consumers with access to compounded versions of Novo Nordisk’s popular obesity drug Wegovy for just $249 per month.
By enabling patients to schedule and pay for appointments with healthcare providers directly on its website, Sesame eliminates the need for intermediaries like insurers.
With the addition of compounded semaglutide, the active ingredient in Wegovy and Novo Nordisk’s Ozempic, Sesame aims to offer a safe and convenient way for users to obtain treatments for obesity and diabetes, especially during a period of scarcity for branded medications. In collaboration with Costco, Sesame already offers a range of branded weight loss and diabetes medications through its platform.
This new program by Sesame presents a more cost-effective option for weight loss, as compounded medications are generally more affordable than their branded counterparts. While Wegovy and Ozempic typically cost around $1,000…
2024-08-21 05:00:01
Article from www.cnbc.com